RxDoctor Payments Data

Ha Huynh, OD

Optometrist · Thibodaux, LANPI 1437604931

Payments from drug & device makers

$2,588in general payments, 2019–2025

Across 62 payments — averaging $41.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Vision Care, Inc.$1K
  • Oyster Point Pharma, Inc.$291
  • Tarsus Pharmaceuticals, Inc.$228
  • Alcon$216
  • AbbVie$190
  • Harrow Eye, LLC$138
  • plus $413 from 8 others

What the payments were for

  • Consulting fees$41016%
  • Food & beverage$2,16083%
  • Gifts$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,588 in reported general payments places this provider in the 70th percentile of 500 optometrist providers in Louisiana.

See all optometrist providers in Louisiana

Medicare billing

Part B allowed, 2024
$35,167
Medicare patients
195
Services billed
496

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine129$94,991
XiidraLifitegrast46$33,562
TyrvayaVarenicline Tartrate35$26,119
LumiganBimatoprost41$19,456
SimbrinzaBrinzolamide/Brimonidine Tart56$12,626
CombiganBrimonidine Tartrate/Timolol13$4,924
Prednisolone Acetate94$3,372
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol21$2,923
Azelastine Hcl71$2,064
Latanoprost321$2,034
Tobramycin-DexamethasoneTobramycin/Dexamethasone30$1,976
Travoprost17$1,921
Brimonidine Tartrate76$1,268
Timolol Maleate81$553
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat41$447

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$190$119,370183 claims
Bausch & Lomb Americas Inc.Xiidra$18$33,56246 claims
Oyster Point Pharma, Inc.Tyrvaya$291$26,11935 claims
AlconSimbrinza$216$12,62656 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 500 optometrist providers in Louisiana.

Other optometrist in Thibodaux

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →